Short Interest in Braveheart Bio, Inc. (NASDAQ:BRVE) Expands By ∞

Braveheart Bio, Inc. (NASDAQ:BRVE) saw a large increase in short interest in August. As of August 14th, there was short interest totaling 847,773 shares, an increase of ∞ from the July 30th total of 0 shares. Based on an average trading volume of 650,680 shares, the short-interest ratio is currently 1.3 days. Currently, 1.2% of the company’s stock are sold short.

Wall Street Analyst Weigh In

BRVE has been the subject of a number of analyst reports. The Goldman Sachs Group started coverage on Braveheart Bio in a report on Monday. They set a “buy” rating and a $48.00 target price for the company. Stifel Nicolaus began coverage on Braveheart Bio in a research report on Monday. They set a “buy” rating and a $45.00 price objective on the stock. Jefferies Financial Group started coverage on shares of Braveheart Bio in a report on Monday. They issued a “buy” rating and a $48.00 target price for the company. Cantor Fitzgerald began coverage on shares of Braveheart Bio in a research report on Monday. They set an “overweight” rating and a $40.00 price target for the company. Finally, Wall Street Zen upgraded shares of Braveheart Bio to a “hold” rating in a report on Saturday, August 15th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $45.25.

Braveheart Bio Price Performance

Shares of BRVE stock opened at $25.50 on Tuesday. Braveheart Bio has a fifty-two week low of $24.31 and a fifty-two week high of $32.00.

Insider Buying and Selling at Braveheart Bio

In other Braveheart Bio news, Director Erez Chimovits bought 1,940,000 shares of the business’s stock in a transaction on Friday, August 7th. The shares were acquired at an average price of $18.00 per share, with a total value of $34,920,000.00. Following the transaction, the director owned 11,901,826 shares of the company’s stock, valued at approximately $214,232,868. This trade represents a 19.47% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Bio Fund Iv L.P. Ah purchased 1,100,000 shares of Braveheart Bio stock in a transaction dated Friday, August 7th. The stock was acquired at an average price of $18.00 per share, with a total value of $19,800,000.00. Following the acquisition, the insider owned 10,232,420 shares in the company, valued at approximately $184,183,560. This represents a 12.05% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have bought 8,751,942 shares of company stock worth $157,534,956.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.